Jeanelle Ahuna
Medical · Honolulu, HINPI 1043463482
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,440 of the $15,855 with a category attached, or 84.8%. 25 manufacturers reported payments, led by Viiv Healthcare Company at 35.6% of the total. Among medical clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $30.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$6K
- Gilead$5K
- AbbVie$1K
- Indivior Inc.$936
- Merck$779
- Boehringer Ingelheim$662
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,10013%
- Food & beverage$13,44085%
- Education$3152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 95 | $5,641 |
| Gilead | 202 | $4,604 |
| AbbVie(2 entities) | 53 | $1,142 |
| Indivior Inc. | 35 | $936 |
| Merck | 31 | $779 |
| Boehringer Ingelheim | 28 | $662 |
| Otsuka America Pharmaceutical, Inc. | 19 | $496 |
| Johnson & Johnson | 23 | $360 |
| Janssen Products, LP | 3 | $278 |
| Novartis | 6 | $152 |
| Novo Nordisk | 1 | $122 |
| Intercept Pharmaceuticals, Inc. | 1 | $118 |
| Alkermes, Inc. | 2 | $114 |
| Madrigal Pharmaceuticals | 3 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $55 |
| EMD Serono, Inc. | 2 | $48 |
| GSK | 2 | $46 |
| Bayer | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Organon | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOVATO$2,313
- APRETUDE$470
- CABENUVA$224
- PERSERIS$168
- ABILIFY MAINTENA$150
- ABILIFY ASIMTUFII$150
- Ozempic$122
- Yeztugo$119
- OCALIVA$118
How this compares
$15,855 in reported general payments places this provider in the 95th percentile of 63 medical providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabenuvaCabotegravir/Rilpivirine | 22 | $143,549 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 30 | $123,378 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $73,687 |
| JulucaDolutegravir/Rilpivirine | 13 | $46,598 |
| TrulicityDulaglutide | 31 | $44,973 |
| OzempicSemaglutide | 26 | $38,557 |
| JardianceEmpagliflozin | 18 | $30,412 |
| MounjaroTirzepatide | 17 | $21,664 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $16,976 |
| TradjentaLinagliptin | 11 | $13,654 |
| LinzessLinaclotide | 15 | $9,394 |
| EntrestoSacubitril/Valsartan | 12 | $9,361 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,973 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 18 | $5,128 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 23 | $4,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyCabenuva, Dovato, Juluca | $5,641 | $263,83557 claims |
| GileadBiktarvy | $4,604 | $123,37830 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $17 | $66,63748 claims |
| Boehringer IngelheimJardiance, Tradjenta | $662 | $44,06629 claims |
| Novo NordiskOzempic | $122 | $38,55726 claims |
| GSKTrelegy Ellipta, Arexvy, Incruse Ellipta | $46 | $26,09956 claims |
| AbbVieLinzess | $1,142 | $9,39415 claims |
| NovartisEntresto | $152 | $9,36112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 medical providers in Hawaii.
Other medical in Honolulu
- Lisa AdamsHonolulu$189K
- Leena HongHonolulu$30K
- Justin MaioHonolulu$12K
- Kelsie LookHonolulu$5K
- Dennis AlvaroHonolulu$3K
- Emma ScheickHonolulu$3K
- Erica FigueiraHonolulu$3K
- Angela PoluHonolulu$2K
- Mary LeonHonolulu$2K
- Larry AuHonolulu$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.